CD4 and neoplasm: Tumor specimens with higher baseline TILs displayed a higher level of antitumor activity: CD8+ and CD4+ T-cells were numerically higher in patients who had evidence of antitumor activity (PR or SD) and CD20+ B-cells were significantly higher in patients who had disease control (PR + SD) compared with patients who had PD (Fig. 2A, B, C, D).